SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair

Cellular and Molecular Life Sciences

Volumn 60, Issue 4, 2003, Pages 794-802

  Zhong, X ^a   Li, Q Q ^a   Reed, E ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

AP 1; Cisplatin; DNA repair; ERCC 1; JNK; Ovarian cancer; SU5416

Indexed keywords

CELL PROTEIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; JANUS KINASE; MESSENGER RNA; PROTEIN C JUN; SEMAXANIB; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC ABSORBANCE SPECTROMETRY; CANCER COMBINATION CHEMOTHERAPY; CELL KILLING; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG SELECTIVITY; EXCISION REPAIR; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; OVARY CANCER; REDUCTION; SPECTROMETRY; VASCULAR ENDOTHELIUM;

CARCINOMA; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; PYRROLES; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED;

JANUS;

EID: 0038025996     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3002-2     Document Type: Article

References (31)

1. Reed E. (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24: 331-344
2. Reed E. (1996) Ovarian cancer: molecular abnormalities. In: The Encyclopedia of Cancer, pp. 1192-1200, Bertino J. R. (ed), Academic Press, San Diego
3. Reed E. (1996) The chemotherapy of ovarian cancer. PPO Updates 10: 1-12
4. Reed E., Dabholkar M. and Chabner B. A. (1996) Platinum analogues. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn., pp. 357-378, Chabner B. A. and Longo D. L. (eds.), Lippincott-Raven, Philadelphia
5. Reed E. (1993) Platinum analogs, anticancer drugs. In: Cancer Principles and Practice of Oncology, pp. 390-400, DeVita V. T., Hellman S. and Rosenberg S. A. (eds), Lippincott, Philadelphia
6. Reed E. (1998) Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 27: 187-201
7. Gosland M., Lum B., Schimmelpfennig J., Baker J. and Doukas M. (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39
8. Dabholkar M. and Reed E. (1996) Cisplatin. Cancer Chemother. Biol. Response Modif. 16: 88-110
9. Parker R. J., Eastman A., Bostick-Bruton F. and Reed E. (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87: 773-777
10. Masuda H., Ozols R. F., Lai G. M., Fojo A., Rothenberg M. and Hamilton T. C. (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48: 5713-5716
11. Lindahl T. and Wood R. (1999) Quality control by DNA repair. Science 286: 1897-1905
12. Lee K. B., Parker R. J., Bohr V., Cornelison T. and Reed E. (1993) Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177-2180
13. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V., Egwuagu C. and Reed E. (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 84: 1512-1517
14. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J. J. and Reed E. (1994) Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94: 703-708
15. Ferry K. V., Hamilton T. C. and Johnson S. W. (2000) Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 60: 1305-1313
16. Li Q., Gardner K., Zhang L., Tsang B., Bostick-Bruton F. and Reed E. (1998) Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J. Biol. Chem. 273: 23419-23425
17. 2+/calmodulin. Immunol. Cell Biol. 77: 356-363
18. Cano E. and Mahadevan L. (1995) Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20: 117-122
19. Adler V., Fuchs S., Kim J., Kraft A., King M., Pelling J. et al. (1995) Jun-NH2-terminal kinase activation mediated by UV-induced DNA lesion in melanoma and fibro cells. Cell Growth Differ. 6: 1437-1446
20. Saleem A., Datta R., Yuan Z., Kharbanda S. and Kufe D. (1995) Involvement of stress-activated protein kinase in the cellular response to 1-D-arabinofunanocytosine and other damaging agents. Cell Growth Differ. 6: 1651-1658
21. Osborne M. and Chambers T. (1996) Role of stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem. 271: 30950-30955
22. Potapova O., Haghighi A., Bost F., Liu C., Birrer M. J., Gjerset R. et al (1997) The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272: 14041-14044
23. Hayakawa J., Ohmichi M., Kurachi H., Mercola D. and Murata Y. (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 274: 31648-31654
24. Angel P. and Karin M. (1991) The role of Jun, Fos and the AP1 complex in cell-proliferation and transformation. Biochem. Biophys. Acta 1071: 129-157
25. Karin M. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270: 16483-16486
26. Reimold A., Grusby M., Kosaras B., Fries J., Mori R., Maniwa S. et al. (1996) Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature 379: 262-265
27. Fong T. A., Shawver L. K. and Sun L. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59: 99-106
28. Mendel D. B. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design 15: 29-41
29. Carmeliet P. and Jain R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
30. Sanchez-Perez I. and Perona R. (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett. 453: 151-158
31. Zhong X., Thornton K. and Reed E. (2000) Computer based analyses of the 5′-flanking regions of selected genes involved in the nucleotide excision repair complex. Int. J. Oncol. 17: 375-380